FILTER
FILTERED INTERVIEW RESULTS
Lucy Pamboukdjian
CHIEF COMMERCIAL OFFICER, BOLSA DE SANTIAGO
The Bolsa de Santiago has made partnerships with regional exchanges as well as with the TSXV in order to maximize the exposure of mining companies in Chile to international investors.
Maria Eugenia Parot
GENERAL MANAGER, GOLDER ASSOCIATES
Golder Associates discuss their business in Chile.
Bart Doyle
GENERAL MANAGER, MAINSTREAM RENEWABLE POWER CHILE
Mainstream Renewable Power are at the forefront of Chile’s dramatic increase in renewable energy production.
John Williamson
PRESIDENT AND CEO, ALTIPLANO MINERALS
Altiplano is developing projects in Chile where it intends to use their cashflow to expand further.
Darko Louit Nevistic
EXECUTIVE VICE PRESIDENT, KOMATSU CUMMINS CHILE
Komatsu Cummins in Peru has extended its offering with the acquisition of Joy Global and is present on the majority of mine sites in the country.
Felipe Malbran
VP OF EXPLORATION, TRIMETALS MINING
Under its new name, TriMetals is bringing forth projects in North and South America with a focus on copper in Chile.
Marcelo Anabalon
GENERAL MANAGER, NORMET
Normet offers an integrated spray concrete service that enables it to dominate the market in Latin America.
Tim Beale
PRESIDENT & CEO, REVELO RESOURCES
Revelo Resources has built up an impressive collection of projects in Chile and is looking for partners with whom to develop them.
Diego Hernández
PRESIDENT, SONAMI
SONAMI is Chile’s chamber of mines and is looking to attract medium sized exploration and production to Chile.
Mark Venning
BUSINESS DEVELOPMENT DIRECTOR, BLACK & VEATCH CHILE
Black & Veatch built and are currently expanding the largest desalination plant in Latin America at BHP Billiton’s Escondida mine in Chile where desalination is becoming fundamental for mining.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
